Literature DB >> 7965739

A functional beta-2 adrenoceptor-mediated chronotropic response in isolated guinea pig heart tissue: selectivity of the potent beta-2 adrenoceptor agonist TA 2005.

H P Voss1, S Shukrula, T S Wu, D Donnell, A Bast.   

Abstract

Responses were measured of the highly potent beta-2 adrenoceptor agonist TA 2005, a new bronchodilator, on isolated guinea pig right and left atria and papillary muscle. The main objectives of the study were to investigate the selectivity of the compound and to determine whether guinea pig isolated heart tissues could be used as a model for investigating mechanisms of clinical cardiac side effects. It was found that the inotropic responses in all tissues were mediated by the beta-1 adrenoceptor only. TA 2005 was a partial agonist for the inotropic response compared with I-isoprenaline. For the right atrial chronotropic response, however, TA 2005 exerted a biphasic effect and reached 84% of the I-isoprenaline response. The first phase was mediated by the beta-2 adrenoceptor, whereas the second phase was beta-1 adrenoceptor mediated. Approximately 64% of the TA 2005 chronotropic response was exerted via the beta-2 adrenoceptor. Addition of the beta-2-selective antagonist ICI 188.551 blocked the beta-2 adrenoceptor-mediated response, providing only a monophasic response. Addition of the beta-1-selective antagonist ICI 89.406 resulted in further separation of the phases. The finding that a beta-2-mediated chronotropic response exists on the right atrium of the guinea pig sheds new light on selectivity studies. It is suggested that quantification of beta-1/beta-2 selectivity of beta adrenoceptor agonists be performed not on the basis of measurement of guinea pig right atrial chronotropism but rather on the basis of measurement of guinea pig left atrial inotropism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965739

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  β(2) -adrenoceptor agonists: current and future direction.

Authors:  Mario Cazzola; Luigino Calzetta; Maria Gabriella Matera
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

Review 2.  ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD?

Authors:  Maria Gabriella Matera; Mario Cazzola
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Tracheal relaxing effects and beta2 adrenoceptor selectivity of S1319, a novel sponge-derived bronchodilator agent, in isolated guinea-pig tissues.

Authors:  H Suzuki; A Ueno; M Takei; K Sindo; T Miura; M Sakakibara; T Higa; H Fukamachi
Journal:  Br J Pharmacol       Date:  1999-10       Impact factor: 8.739

4.  Increased response to β₂-adrenoreceptor stimulation augments inhibition of IKr in heart failure ventricular myocytes.

Authors:  Hegui Wang; Yanhong Chen; Hongjun Zhu; Sen Wang; Xiwen Zhang; Dongjie Xu; Kejiang Cao; Jiangang Zou
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

Review 5.  Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease.

Authors:  Robert M Burkes; Ralph J Panos
Journal:  J Exp Pharmacol       Date:  2020-12-14

Review 6.  Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review.

Authors:  Erminia Ridolo; Marcello Montagni; Elisa Olivieri; Gian Galeazzo Riario-Sforza; Cristoforo Incorvaia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-09-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.